SavedAdd your journal

Journals / Pamukkale Tıp Dergisi / 2022 / Cilt: 15 - Sayı: 3

How has the COVID-19 disease affected patients with kidney stones?

COVID-19 hastalığı böbrek taşı olan hastaları nasıl etkiledi?

Mesut Berkan DURAN
Samet ŞENEL
Tuğba İZCİ DURAN
Taha Numan YIKILMAZ
Serdar TOKSÖZ
Pages
611–618
Publication Date
2022-07-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: The duration of COVID-19 treatment was longer and the COVID-19 infection was more severe in those with kidney stones.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To evaluate the relationship between the presence of kidney stones and COVID-19.Materials and methods: Patients, who were treated for COVID-19 as outpatients as well as inpatients in the ward and/or ICU of two different secondary and tertiary care centers between July 15, 2020, and December 31, 2020, and aged ≥18 years were retrospectively evaluated.
📊
Key Findings & Data:The patients were divided into two subgroups based on the presence of kidney stones, and then the patients with kidney stone were categorized into three groups: those who were treated in an outpatient setting (Group 1), those who were treated in the ward (Group 2), and those who were treated in the intensive care unit (Group 3).Results: The total of 1,335 COVID-19 patients included in the study.
💡
Conclusion & Impact:Conclusion: The duration of COVID-19 treatment was longer and the COVID-19 infection was more severe in those with kidney stones.
🔬Design:Research Article
📍Scope:2020 Verileri
⚙️Variables:COVID-19 · Böbrek taşı · nefrolitiazis

Abstract

Purpose: To evaluate the relationship between the presence of kidney stones and COVID-19.Materials and methods: Patients, who were treated for COVID-19 as outpatients as well as inpatients in the ward and/or ICU of two different secondary and tertiary care centers between July 15, 2020, and December 31, 2020, and aged ≥18 years were retrospectively evaluated. The patients were divided into two subgroups based on the presence of kidney stones, and then the patients with kidney stone were categorized into three groups: those who were treated in an outpatient setting (Group 1), those who were treated in the ward (Group 2), and those who were treated in the intensive care unit (Group 3).Results: The total of 1,335 COVID-19 patients included in the study. Kidney stone was present in 31 (6.9%) of 450 outpatients, 41 (8.9%) of 460 inpatients treated in the ward, and 60 (14.1%) of 425 inpatients treated in the intensive care unit. In Group 1, the duration of COVID-19 treatment was significantly longer in patients with kidney stone than patients without kidney stone (8.1±1.7 vs. 6.8±2.2 days, p=0.01). In Group 2 and in Group 3, the mean hospitalization duration was significantly longer in patients with kidney stone than in those without kidney stone (9.1±3.7 vs. 6.2±2.1 days, p=0.007; 19.1±8.1 vs. 11.3±6.2 days, p=0.001, respectively). Conclusion: The duration of COVID-19 treatment was longer and the COVID-19 infection was more severe in those with kidney stones.

Özet

Amaç: Böbrek taşı varlığı ile COVID-19 hastalığı arasındaki ilişkinin değerlendirilmesiGereç ve yöntem: COVID-19 tanısı ile 15 Kasım-31 Aralık 2020 tarihleri arasında 2. ve 3. basamak 2 farklı merkezde ayaktan, servis ve/veya yoğun bakımda tedavi uygulanan hastalar retrospektif olarak tarandı. Öncelikle hastalar böbrek taşı varlığına göre alt gruplara ayrıldı ve daha sonra böbrek taşı olan olgular, ayaktan tedavi gören hastalar Grup 1, serviste yatarak tedavi gören hastalar Grup 2 ve yoğun bakımda tedavi ihtiyacı doğan olgular ise Grup 3 olarak kategorize edildi.Bulgular: Çalışmaya toplam 1335 COVID-19 hastası dahil edildi. Ayaktan tedavi edilen 450 hastanın 31'inde (%6,9), serviste yatan 460 hastanın 41'inde (%8,9) ve yoğun bakımda yatan 425 hastanın 60'ında (%14,1) böbrek taşı mevcuttu. Grup 1'de, böbrek taşı olan hastalarda COVID-19 tedavi süresi böbrek taşı olmayan hastalara göre anlamlı olarak daha uzundu (8,1±1,7 ve 6,8±2,2 gün, p=0,01). Grup 2 ve Grup 3'te ortalama hastanede kalış süresi böbrek taşı olan hastalarda böbrek taşı olmayanlara göre anlamlı olarak daha uzundu (sırasıyla 9,1±3,7 ve 6,2±2,1 gün, p=0,007; 19,1±8,1 ve 11,3±6,2 gün, p=0,001).Sonuç: Böbrek taşı olanlarda COVID-19 tedavi süresinin daha fazla ve COVID-19 enfeksiyonunun daha şiddetli olduğu saptandı.

🔖

Cite This Article

DURAN, M. B., ŞENEL, S., DURAN, T. İ., YIKILMAZ, T. N., TOKSÖZ, S. (2022). How has the COVID-19 disease affected patients with kidney stones?. Pamukkale Tıp Dergisi, Cilt: 15 - Sayı: 3, 611–618. https://ajindex.com/articles/696381

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Erensoy, S., SARS-CoV-2 and Microbiological Diagnostic Dynamics in COVID-19 Pandemic. Mikrobiyoloji bulteni, 2020. 54(3): p. 497-509
  2. Krishnan, A., et al., A narrative review of coronavirus disease 2019 (COVID-19): clinical, epidemiological characteristics, and systemic manifestations. Intern Emerg Med, 2021: p. 1-16
  3. Mehta, P., et al., COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet, 2020. 395(10229): p. 1033-1034
  4. Yoshikawa, T., et al., Severe acute respiratory syndrome (SARS) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells. J Virol, 2009. 83(7): p. 3039-48
  5. Yuki, K., M. Fujiogi, and S. Koutsogiannaki, COVID-19 pathophysiology: A review. Clin Immunol, 2020. 215: p. 108427
  6. Pirola, C.J. and S. Sookoian, Age but not sex may explain the negative effect of arterial hypertension and diabetes on COVID-19 prognosis. J Infect, 2020. 81(4): p. 647-679
  7. Ragab, D., et al., The COVID-19 Cytokine Storm; What We Know So Far. Front Immunol, 2020. 11: p. 1446
  8. López-Lluch, G., et al., Mitochondrial responsibility in ageing process: innocent, suspect or guilty. Biogerontology, 2015. 16(5): p. 599-620
  9. Moreno Fernández-Ayala, D.J., P. Navas, and G. López-Lluch, Age-related mitochondrial dysfunction as a key factor in COVID-19 disease. Exp Gerontol, 2020. 142: p. 111147
  10. Sorokin, I., et al., Epidemiology of stone disease across the world. World Journal of Urology, 2017. 35(9): p. 1301-1320
  11. Scales, C.D., Jr., et al., Prevalence of kidney stones in the United States. Eur Urol, 2012. 62(1): p. 160-5
  12. Patel, M., et al., Oxalate induces mitochondrial dysfunction and disrupts redox homeostasis in a human monocyte derived cell line. Redox Biol, 2018. 15: p. 207-215. 13. de Lucena, T.M.C., et al., Mechanism of inflammatory response in associated comorbidities in COVID-19. Diabetes Metab Syndr, 2020. 14(4): p. 597-600
  13. Zhu, N., et al., A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med, 2020. 382(8): p. 727-733
  14. Darisipudi, M.N. and F. Knauf, An update on the role of the inflammasomes in the pathogenesis of kidney diseases. Pediatr Nephrol, 2016. 31(4): p. 535-44
  15. Joosten, L.A.B., et al., Asymptomatic hyperuricaemia: a silent activator of the innate immune system. Nat Rev Rheumatol, 2020. 16(2): p. 75-86
  16. Mulay, S.R., A. Evan, and H.J. Anders, Molecular mechanisms